Fondation Louis-Jeantet de Médecine (FLJ)

Fondation Louis-Jeantet de Médecine (FLJ)

The Louis-Jeantet Foundation was set up in Geneva in 1982 according to the wish of the French businessman Louis Jeantet, who was a resident of the Swiss city. The Foundation was endowed with his fortune, when he died in 1981. It started its activities in 1983, funding the Louis-Jeantet Prize and a number of professorships at the Faculty of Medicine of the University of Geneva. (www.jeantet.ch)

The Louis-Jeantet Prizes

Established in 1986, the Louis-Jeantet Prizes are awarded each year to experienced researchers who have distinguished themselves in the field of biomedical research in one of the member states of the Council of Europe. They are not intended solely as the recognition of work that has been completed, but also as an encouragement to continue innovative research projects. The prizes are awarded to fully active researchers who focus on biomedical research.

The Jeantet-Collen Prize for Translational Medicine

Established in 2019, the Jeantet-Collen Prize for Translational Medicine can be awarded each year to experienced researchers who have distinguished themselves in biomedical research with a strong clinical application in Europe. Like the Louis-Jeantet Prize for Medicine, the Jeantet-Collen Prize for Translational Medicine is not intended as the recognition for work that has been completed, but rather as an encouragement to the continuation of research projects of major importance to clinical medicine.

Laureates of the Jeantet-Collen Prize for Translational Medicine

2019

Luigi NALDINI, of Italian nationality, was awarded the 2019 Jeantet-Collen Prize for Translational Medicine for his pioneering work taking gene therapy from the bench to the bedside, allowing to treat several genetic diseases. 

2020

Graziella PELLEGRINI and Michele DE LUCA, of Italian nationality, shared the 2020 Jeantet-Collen Prize for Translational Medicine for the development of epithelial stem cell-based regenerative therapy in patients with severe eye and skin disease.

2021

Jérôme GALON, of french nationality, and Tom SCHUMACHER, of Dutch nationality, will share the 2021 Jeantet-Collen Prize for Translational Medicine for the development of technologies to study the role of the immune system in cancer and for the improvement of cancer diagnosis and treatment

2022

Uğur ŞAHIN and Özlem TÜRECI, of German nationality and Katalin KARIKÓ, of Hungarian nationality, will share the 2022 Jeantet-Collen Prize for Translational Medicine for the design and development of mRNA-based vaccines that safely protect humankind against the deadly SARS-CoV-2 virus.

 

2023

Dario ALESSI, of British nationality, is awarded the 2023 Jeantet-Collen Prize for Translational Medicine for elucidating molecular bases of neurodegenerative disorders and developing novel approaches to therapeutic intervention in Parkinson’s disease.

2024

Charles SWANTON, of British nationality, is awarded the 2024 Jeantet-Collen Prize for Translational Medicine for his groundbreaking discoveries in cancer genetics and evolution, leading to insights into how tumours evolve, spread and develop resistance to drugs.

 

Grant of DCS/DCF to Louis Jeantet Fund (LJF) 2019 – 2021

DCS/DCF and LJF entered into an agreement on December 14, 2018 to install an annual European Jeantet-Collen Prize for Translational Medicine during 2019-2021.

Continued Grant of DCS/DCF to FLJ beyond 2021

DCS/DCF and LJF entered into an agreement on April 30, 2020 to continue the annual European Jeantet-Collen Prize for Translational Medicine for renewable cycles of three years beyond 2021.